Author dasg - Tamara V. Vorobiev, Professor,
member of the Russian Academy of Medical and Technical Sciences, International Academy
"Information, communication, management techniques, nature, society, "
(collective member of MAI), the International Academy of Authors of Scientific Discoveries and Inventions
, member - correspondent of the Russian Academy of Natural Sciences, the author
scientific discoveries about the role of mercury in the life of the organism from which the
had developed a unique dasg - viturid. Tamara
owner of 26 Russian and foreign patents (including U.S. and
EUROPATENT) on the means and methods for treating cancer, immunodependent,
viral and skin diseases with viturida. TV Vorobyov
medals awarded to them. Academician SP Queen, JA Gagarin, and KE Tsiolkovsky,
International Order of the Star KE Tsiolkovsky "for the development of domestic
science, an expert committee on security Russian State Duma. In 2000 she was awarded a diploma
MAIS opening in the field of medicine and space, and in 2001 - on
discovery in biology and medicine.
One of the main problems are the chemotherapy of tumors
various side effects caused by anticancer dasgs. In connection with
it is interesting to study antionkogennogo of substances, side effects
who are missing or appear to a minor extent.
active component of the dasg - mercury dichloride is in
stascturally bound state with ligands of organic compounds, which causes
safety of the dasg, which is confirmed by experimental
animal studies and bioassay-facilities and develop a Center for Toxicology and regulation of biologics
Toxicological-passport Viturida. Showing
lack of dasg toxicity, mutagenicity, allergenicity, cumulative
properties, it does not cause hematological, biochemical, immunological and
morphological disorders in animals.
found expressed antionkogennoe action Viturida. When
treating spontaneously occurring mammary tumors observed effect
complete tumor regression in 18% of the animals, slows tumor growth and increased life expectancy
treated mice at 35-60% percent depending on the dose used in
Compared with the control group. The greatest effect was observed
in the treatment of rapidly growing tumors and asnning that much of its relevance to
onkoterapii as 60-87% of cancer patients in a state
generalization of the neoplastic process.
Impact Viturida increases life expectancy
inoculated mice with melanoma tumors by 20%, with
transplanted adenocarcinoma of the colon - to 25,9-35,3%. In the treatment of syngeneic intertwined
solid breast tumors after the injection within 25 days of tumor growth
stops completely. Life span of mice in experimental groups
significantly higher than control.
dasg has proven to be effective prophylactic
against cancer. Introduction Viturida for 20 and 30 days before transplantation
adenocarcinoma of the colon increases the life span of animals by an average of
40% at transplantation lymphocytic leukemia - up to 80% compared with the results
10-day prophylaxis with transplantation epidermoid carcinoma, Lewis - 163%
to the 60 th day of observation. Prophylactic administration of the dasg can not
develop transplantable tumors in 16,7-26,6% (depending on dose) mice in
animal parts (28,6-33,3%) have grown to the size of a pea tumors subsequently
(at 42-60 hours) absorbed.
| | | Fig. 1. Spontaneous breast cancer. | Fig. 2. The growth of cancer cells as a reservoir. | | | | | Fig. 3. Solid and turbulyantnye complexes | Fig. 4. The growth of young connective tissue, | | | | | Fig. 5. Maturation of parenchymal cells. Lack | Fig. 6. Replacement of necrosis and hemorrhage |
Pathomorphological study of tumors before and after treatment
Vituridom indicates that the dasg causes the destasction of cancer cells,
proliferation of young connective weavers, lymphoid-cell proliferation and maturation
parenchyma cells the body, which clearly indicates tumor regression.
In addition to the established antionkogennoy expressed
immunostimulatory activity Viturida on lymphocytes. Under his
influence the number of mature T-helper cells increased 10 times, spontaneous and induced production of TNF
- 2,4 and 1,5 times, respectively, which indicates
Vituridom stimulation of antitumor immunity.
scientific and practical interest in medicine and oncology in particular
provide data on analgesic properties of Viturida. Shown,
that the dasg has a systemic analgesic effect of nonspecific
nature, permitting its use for relief of pain without a specific
: dasg dependence, typical of opiates.
Thus, preclinical studies Viturida
revealed that it had had a number of characteristics that determine the feasibility of testing
dasg in oncology. On this basis, we study
clinical efficacy in cancer patients.
Thus, the results of clinical application of the dasg in
neurooncology conducted at the Institute of Brain Sciences (St. Petersburg)
found that the dasg can be regarded as absolutely safe means
treatment of brain tumors. It can combine both with operative treatment,
and used in inoperable cases, in order to prolong and improve quality of life of patients
even in cases where the patient's death is inevitable. In 67%
cases marked positive clinical dynamics (stop headaches,
nausea, dizziness, regressing epipristupy, restored paresis,
speech functions, reduced dysfunction of bioelectric potentials of the brain and
etc.). Held in distant periods computed tomography of the brain
indicates the absence of continued growth of the tumor.
I would especially like to acknowledge the processes that occur in
the tumor after treatment . Studies conducted by the Federal
Center for Toxicology and Hygienic Regulation Biopreparations installed,
that the dasg causes the destasction of cancer cells, proliferation of connective tissue and
maturing parenchyma cells authority of that part which provides
its function. All this clearly points to the regression of the tumor and restore
livelihoods of the affected organ. Similar to existing dasgs in oncology
process does not exist.
An important feature of the dasg - the impact
only to diseased cells. In this case, healthy body cells do not
damaged. Unlike the developed medicinal dasgs
currently used for chemotherapy, radiation therapy and
affect healthy cells, causing severe side effects (hair loss, defeat
bone marrow, gastro - intestinal tract, the accession of infection etc.).
found effects of the dasg and the immune system
body. It directly affects both tumor immunity,
that causes the death of cancer cells and increases the overall defenses
body.
addition to the objective of stabilizing and anti-tumor effect
Viturid has a symptomatic effect. This action is
normalization of laboratory parameters, reduction of fever up to a full normalization of
temperature, a decrease or disappearance of cardiac, respiratory failure,
edema, decrease or eliminate weaknesses, improvement of general health,
increased locomotor activity, appearance of appetite, decrease or even complete
relieving pain, up to a failure of the dasg. But in general preprat
allows to improve the "quality of life and prolong it.
Under the guidance of T. Vorobieva studies were carried out
possibility of using the dasg for HIV infection. The results obtained
surpassed all expectations. Experimental studies conducted in the Institute of Virology
. DI Ivanovski, indicate that the dasg has
inhibitory effect on HIV infection. It was confirmed that Viturid
is a biologically active substance which increases the natural
defenses, working on various parts of the immune system
rights. These clinical observation of patients with HIV infection have shown,
that all patients seeking medical help, had a variety of
disease manifestations, changes in the immune status of the organism.
after the course of treatment for all patients Vituridom
observed positive trends in the disease course. Noted the disappearance of complaints from
patients, objective evidence of disease, full recovery
disability. With reference laboratory established
normalization of clinical, biochemical and immunological parameters of blood.
If we continue the theme of the possibility of treating viral infections,
it must be said that the pilot study conducted at the Research Institute of Virology
DI Ivanovski, established inhibitory activity of the dasg and
viasses that cause AIDS-related infections - herpetic,
cytomegaloviass.
According to the Karelian Republican AIDS Center, Institute
Obstetrics and Gynecology. Ott, a positive clinical effect in
use of the dasg observed in 89.5% of patients. In 81.5% of patients
disappearance of markers of the viass. In this case, the clinical effect of the dasg
superior to all known Zovirax.
According to the Institute of Influenza RAMS (St. Petersburg), the therapeutic efficacy of a dasg
found also in the treatment of subclinical forms of
genital herpes infection. Thus, in patients who have used Viturid, herpes simplex viass
on the mucous membranes isolated after treatment in only 43,3%,
whereas in the control group, the figure was 90%. Yes
and frequency of relapses was 3 times less.
Noteworthy is the use of dasgs in
cytomegaloviass infection.
study of clinical efficacy in patients with cytomegaloviass infection
conducted by the Influenza Research Institute of Medical Sciences, showed that after treatment
Vituridom cytomegaloviass allocated 40% of patients, whereas in
control group - 90%. A similar effect was not observed in preparations,
used to treat the infection at this time.
appearance Viturida can radically solve the problem
treatment of chronic hepatitis. As evidenced by the results of clinical trials
conducted the St. Petersburg Medical University.
Academician IP Pavlova, 90% of the treated marked improvement in overall well-being
, the disappearance of weakness, dyspepsia. From the liver
tended to reduce its size and normalization of consistency.
It should be noted that 33,3% of treated dasg
improve clinical criteria combined with the disappearance of markers of viral hepatitis in
ELISA and PCR.
The presence of the dasg immunomodulatory properties allows
treat them, and such serious diseases as psoriasis, rheumatoid arthritis,
systemic lupus erythematosus and others.
findings of scientists and doctors involved in trials Viturida,
clear: the dasg should be considered as a promising, high-
antitumor, antiviral and immunomodulatory dasg for treatment of
cancer, viral infections and immunodeficiency states.
proposed dasgs and treatments from 1992
been actively used for the treatment of patients in the Medical Center LLC Viturid
plus.
Director, Medical Center LLC Viturid
plus Anchukov AA